CIM
PTCT icon

Contravisory Investment Management’s PTC Therapeutics PTCT Stock Holding History

Contravisory Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-339
Closed -$13.8K – 373
2023
Q2 		$13.8K Hold
339
– – ﹤0.01% 261
2023
Q1 		$16.4K Buy
339
+231
+214% +$10.6K ﹤0.01% 255
2022
Q4 		$4.12K Hold
108
– – ﹤0.01% 298
2022
Q3 		$5K Buy
+108
New +$5.29K ﹤0.01% 283

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Contravisory Investment Management's PTCT Position: Q3 2023 in Review

Contravisory Investment Management sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 339 shares — an estimated $13.8K sold.

Contravisory Investment Management first reported a position in PTCT in Q3 2022 and held it in 4 quarters. The position peaked at $16.4K in Q1 2023. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Contravisory Investment Management reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Contravisory Investment Management sold 339 PTC Therapeutics shares in Q3 2023, an estimated $13.8K.
  • Contravisory Investment Management first reported a position in PTC Therapeutics in Q3 2022 and held it in 4 quarters.
  • Contravisory Investment Management's PTC Therapeutics position peaked at $16.4K in Q1 2023.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Contravisory Investment Management's 13F filing for Q3 2023, filed 10 Oct 2023.